StockData
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc (MREO) stock

MREONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 1/30
$0.29+0.01 (+5.39%)

Close on Nov 18, 2026Market cap $46.20MP/E –Yield –

Mereo BioPharma r&d expenses

Research and development expenses are spending on new products and technology.

Mereo BioPharma's R&D Expenses for the twelve months ending Sep 30, 2026 was $12.84M, down 42.7% year over year. For fiscal 2025 it was $17.77M, down 15.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.77M-15.1%
FY2024Dec 31, 2024$20.93M+20.2%
FY2023Dec 31, 2023$17.42M-40.9%
FY2022Dec 31, 2022$29.47M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.09M-51.1%
Q2 FY2026Jun 30, 2026$1.81M-66.4%
Q1 FY2026Mar 31, 2026$4.75M+20.8%
Q4 FY2025Dec 31, 2025$4.19M-52.5%
Q3 FY2025Sep 30, 2025$4.27M+34.7%
Q2 FY2025Jun 30, 2025$5.37M+8.6%
Q1 FY2025Mar 31, 2025$3.93M-1.6%
Q4 FY2024Dec 31, 2024$8.82M+83.6%
Q3 FY2024Sep 30, 2024$3.17M-11.8%
Q2 FY2024Jun 30, 2024$4.95M+33.2%
Q1 FY2024Mar 31, 2024$3.99M-24.7%
Q4 FY2023Dec 31, 2023$4.80M–
Q3 FY2023Sep 30, 2023$3.59M–
Q2 FY2023Jun 30, 2023$3.71M–
Q1 FY2023Mar 31, 2023$5.31M–

More Mereo BioPharma figures

See a number that looks wrong?